跳至主要内容
临床试验/NCT02245282
NCT02245282已完成不适用

Contrast Enhanced MRI of the Prostate

OHSU Knight Cancer Institute1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2017年2月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
14
试验地点
1
主要终点
Prostate Cancer Detection and Aggressiveness Monitoring by Contrast Enhanced MRI

研究概览

简要总结

Prostate cancer detection and disease progression monitoring relies on systematic multi-core biopsies. Minimal invasive imaging capacities for lesion targeting and monitoring are badly needed. The purpose of this study is to determine if a new MRI technique can identify and monitor prostate disease progression. If so biopsy core number can be reduced to as small as one, and frequency for biopsy repeat can be reduced. The new technique is about a new way of analyzing the pictures taken as part of prostate MRI exam. This part is called dynamic contrast-enhanced MRI. It involves an injection of contrast reagent (or dye) through the arm vein during a time period when prostate MRI pictures are continuously taken.

详细描述

The aim of the study is to perform contrast-enhanced (CE) magnetic resonance imaging (MRI) at OHSU on subjects with diagnosed prostate cancer. This pilot project will study 20 subjects prior to their next scheduled clinical procedures (biopsy or radical prostatectomy). Data from this project will be used to explore new capabilities of the software platform developed under current SBIR funding. CE-MRI will involve the use of an extracellular (Gadolinium based, Gd) contrast agent. When Gd is used, (dynamic-contrast-enhanced) DCE-MRI signal intensity time-course data will be analyzed analytically using the so called "shutter-speed" paradigm which takes into account of the effects of finite water exchange kinetics. Region of interest (ROI) and high resolution (~millimeter) parametric maps of pathophysiologic quantities, such as tumor vessel permeability, tumor perfusion, extracellular extravascular volume fraction, will be generated from the DCE-MRI data. All parameters will be compared to literature results for software validation and correlated with pathology for clinical potential.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Men, age >18 years.
  • Any patient scheduled for prostate biopsy repeat or radical prostatectomy.
  • Ability to understand and the willingness to sign a written informed consent document.

排除标准

  • Patients who would be normally excluded from undergoing an MRI examination - patients with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of a strong magnetic field.
  • Patients who are unable to cooperate for an MRI exam.
  • Major surgery within a month of enrollment.
  • Prostate biopsy six weeks prior to enrollment.
  • Subject-reported reaction to gadolinium contrast reagent.

结局指标

主要结局

Prostate Cancer Detection and Aggressiveness Monitoring by Contrast Enhanced MRI

时间窗: within 60 days after MRI data collection

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mark Garzotto, MD

Professor

OHSU Knight Cancer Institute

研究点 (1)

Loading locations...

相似试验

Contrast Enhanced MRI of the Prostate | 临床试验